TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A USC Schaeffer Center model estimates donanemab treatment for Alzheimer’s could generate $104,900 in lifetime societal value per person when begun at the timing reflected in a clinical trial. Starting two years earlier raised the modeled value to $138,300, but the estimates exclude drug, screening and monitoring costs and depend on uncertain treatment effects over time.
A new USC Schaeffer Center model estimates that starting the Alzheimer’s drug donanemab two years earlier could raise its lifetime societal value by 32%, to $138,300 per person, compared with treatment timing modeled on a clinical trial. The study, published Oct. 7 in Alzheimer’s & Dementia, projects gains in survival, independent living and reduced caregiving, but does not subtract the costs of the drug or the screening and monitoring needed to provide it.
Researchers modeled three scenarios for a group similar to participants in a pivotal Phase 3 trial: receiving donanemab at the trial’s treatment timing, starting it two years earlier after symptoms typically emerge, or receiving no treatment. The model estimated that treatment at the trial timing would add about 0.3 years of life and reduce time spent with severe dementia by one year compared with no treatment. It also projected gains of 0.37 disability-free years and 0.63 years living in the community.
Those projected health and economic benefits amounted to $104,900 in lifetime value per person, according to the study. About $52,300 was attributed to improved health-related quality of life, $23,800 to lower unpaid caregiving and $22,200 to medical cost offsets, largely accruing to Medicaid. The model estimated Medicaid costs would fall by about $1,640 a year, or 13%, for the treated group.
When treatment began two years earlier, the estimated lifetime value increased to $138,300. A separate scenario that assumed potentially stronger treatment effects raised the estimate to $179,400, 71% above the trial-timing scenario. The researchers modeled a 29% slowing of disease progression for the main treatment scenarios, matching the trial result against placebo after 18 months. These are model projections, not observed outcomes for patients followed over their lifetimes.
Earlier Diagnosis Could Change Treatment Value
The estimates address a practical question for health systems and families: whether diagnosing Alzheimer’s sooner could make treatments that slow decline more valuable over time. The study’s modeled benefits extend beyond patients’ health to unpaid care partners and public programs that pay some dementia-related costs. That wider accounting matters because the burden of care is not limited to the price of medical treatment.
Earlier identification could be particularly relevant because Alzheimer’s is diagnosed, on average, 3.5 years after symptoms first appear, according to the report. The researchers argue that investments in detection could help eligible patients reach treatment earlier. The model does not establish that every patient will experience these gains, nor does it show that earlier treatment is cost-effective once all delivery costs are counted. Those questions require evidence on clinical outcomes, access and costs.
Alzheimer's disease early detection kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Modeling Treatment Timing and Costs
The researchers used a dynamic microsimulation model developed for the USC Schaeffer Center’s U.S. Cost of Dementia Project, a federally funded effort to estimate dementia’s costs. They drew on national health surveys and research on disease progression to project cognitive status and lifetime outcomes. The analysis focused on donanemab, marketed as Kisunla, an anti-amyloid treatment designed to target amyloid plaque buildup in the brain.
The report says several blood-based biomarker tests received FDA approval in the preceding year, while digital cognitive assessments are also emerging as possible tools for earlier identification. These developments may help address the diagnosis gap, but the study did not evaluate a screening program or establish how many people would be diagnosed earlier in routine care. The modeled value figures include health and economic benefits, not drug, screening or monitoring expenses.
The researchers also tested how long benefits might last. If donanemab’s effect persisted for only four years rather than the patient’s remaining lifetime, the modeled value fell by about half, to $49,100 at trial timing. Starting two years earlier still produced an estimated $56,400 in that scenario, 15% more. The report also modeled hypothetical future medicines that slow disease more substantially, but those estimates are projections rather than results for available therapies.
“Our research suggests that investments in early detection could help ensure that patients start treatments when they’re more likely to provide the greatest benefit to patients and society.”
— Jack Chapel, lead author and USC Schaeffer scholar
Treatment Duration and Net Costs
It is not yet clear how long donanemab’s benefits persist beyond the clinical evidence used in the model. The researchers’ four-year scenario substantially reduced estimated lifetime value, showing how sensitive projections are to treatment duration. The analysis also does not determine whether the modeled gains outweigh the total costs of the drug, diagnostic testing, monitoring or any additional care required during treatment.
The study models a population resembling trial participants, so its estimates may not apply equally to all people with Alzheimer’s. The supplied report does not give a dollar estimate for the uncertainty ranges around the main projections. Whether earlier detection can be achieved equitably, and how many newly identified patients would be eligible for treatment, also remain unresolved.
Evidence Needed on Real-World Use
The study does not announce a change in treatment guidance or coverage policy. Further research will be needed to establish how treatment effects persist over longer periods and how projected benefits compare with the full costs of diagnosis, medicine and monitoring. Health systems and policymakers would also need evidence on whether earlier testing leads to earlier treatment for eligible patients in routine practice.
The authors point to a broader pipeline of Alzheimer’s medicines, with more than 150 drugs in clinical testing, according to the report. Their modeled estimates for treatments that slow or halt progression are hypothetical and will depend on whether future therapies prove effective and how they are delivered. For now, the study provides estimates for weighing treatment timing—not a guarantee of individual benefit or a complete calculation of affordability.
Key Questions
What did the study estimate about earlier donanemab treatment?
The model estimated that starting treatment two years earlier could raise lifetime societal value per person from $104,900 to $138,300, a 32% increase over the trial-timing scenario. These are projections, not observed lifetime results.
What does the study mean by societal value?
The estimate combines modeled health-related quality-of-life benefits with reduced unpaid caregiving and medical cost offsets. It is not the drug’s market price or a direct estimate of savings for every patient or household.
Does the value estimate include the cost of donanemab?
No. The study’s estimates exclude the cost of the drug and the screening and monitoring needed to deliver treatment. The figures therefore do not by themselves show whether treatment is cost-effective.
How certain are the projected benefits?
They depend in part on how long treatment effects last. In a scenario where effects lasted four years rather than the rest of a patient’s life, modeled value fell to $49,100 at trial timing and $56,400 with treatment begun two years earlier.
Why does earlier diagnosis matter to this analysis?
The report says Alzheimer’s is diagnosed an average of 3.5 years after symptoms begin. The model suggests treatment may provide greater value when started earlier, but it does not test a screening program or establish who would qualify for treatment.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
